Real-life safety of peanut oral immunotherapy: Results from a French multicenter observational study
Although POIT is safe for most patients, some severe IARs influenced by cofactors may occur several months after the beginning of the process. These results highlight the overriding importance of maintaining therapeutic education, especially about risk cofactors, throughout oral immunotherapy programs.
Institutions
- Inserm (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Hôpital Jeanne de Flandre (FR)
- Hôpital Robert-Debré (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Développement, Adaptation et Handicap
- Université de Lorraine (FR)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1016/j.jacig.2025.100628
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00